期刊文献+

肺腺癌中VEGF家族及其受体表达与FDG摄取程度的关系

The correlation of vascular endothelial growth factor family and the receptors with FDG uptake in lung adenocarcinoma
原文传递
导出
摘要 目的研究肺腺癌中血管内皮生长因子D及其受体表达水平与病灶氟代脱氧葡萄糖(FDG)摄取程度的关系,探讨FDG摄取程度是否可作为肺腺癌中预测靶向治疗疗效的一项指标。方法使用寡DNA基因芯片技术(Genespring 7.3)对6例肺腺癌病例行基因水平分析,并使用免疫组化方法对基因分析进一步证实。使用抗VEGF-D抗体对49例肺腺癌病理石蜡包埋切片行免疫组化染色。所有患者常规行PET检查,感兴趣区的定量分析采用标准摄取值(SUV)。使用独立样本t检验,χ2检验及F检验行统计学分析,使用Kaplan-Meier方法计算无病生存曲线。结果 VEGF-D表达在低FDG摄取组中远远高于高FDG摄取组(=0.0241)。免疫组化研究进一步证实:VEGF-D阴性组的FDG摄取程度明显高于阳性组(<0.001)。VEGF-D高表达组中发生淋巴结转移(<0.001)及复发(<0.001)的病例数均明显低于VEGF-D低表达组。VEGF-D高表达的患者其无病生存率明显高于低表达者。结论 VEGF-D表达与肺腺癌患者FDG摄取程度呈负相关,且可能作为肺腺癌患者淋巴结转移,组织学分型及复发的预测指标。 Objective We investigated the correlation between fluorodeoxyglucose (FDG) uptake on PET and the expression of vascular endothelial growth factor-D(VEGF-D) and VEGFRs in lung adenocarcinoma to find out whether PET can be a predictor for the target therapy. Methods The gene level study was achieved by oligo DNA microarray and analysed with Genespring 7.3 software. For further confirmation of protein level, VEGF-D immunohistochemical analysis was applied on consecutive paraffin-embedded sections obtained from 49 resected lung adenocarcinoma samples. All of the patients underwent both PET and surgery. Results The gene level expression of VEGF-D in low FDG uptake group was higher than that in high FDG uptake group ( P= 0.0241). FDG uptake was significantly higher ( P〈0.001), lymph node metastasis ( P〈0.001 both) and recurrence ( P〈0.001 and = 0.001 separately) occurred much often in VEGF-D negative group than in VEGF-D positive group. Patients with low VEGF-D had much better disease-free survival probabilities ( P 0.001). Conclusion VEGF-D expression is negatively correlated with FDG uptake ( P〈0.001), which might be an indictor for lymph node metastasis, histological subtypes and recurrence in lung adenocarcinoma.
出处 《解剖科学进展》 CAS 2010年第3期230-234,239,共6页 Progress of Anatomical Sciences
关键词 肺腺癌 氟代脱氧葡萄糖 血管内皮生长因子D 血管内皮生长因子受体 lung adenocarcinoma fluorodeoxyglucose vascular endothelial growth factors (VEGFs) vascular endothelial growth factor receptors (VEGFRs)
  • 引文网络
  • 相关文献

参考文献15

  • 1Breathnach OS,Freidlin B,Conley B,et al.Twenty-two years of phase Ⅲ trials for patients with advanced non-small-cell lung cancer:sobering results[J].J Clin Oncol,2001,19:1734-1742.
  • 2Folkman J.What is the evidence that tumors are angiogenesis dependent[J]? J Natl Cancer Inst (Bethesda),1990,82:4-6.
  • 3Sandier A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,14:2542-2550.
  • 4Cuo J.Tumor angiogenesis in lung adenocarcinomas:correlation with 18F-FDG uptake and prognosis[J].J Kanazawa Med Univ,2006,31:10-16.
  • 5Tammela T,Enholm B,Alitalo K,et al.The biology of vascular endothelial growth factors[J].Cardiovasc Res,2005,65:550-563.
  • 6Cebe-Suarez S,Zehnder-Fjallman A,Ballmer-Hofer K.The role of VEGF receptors in angiogenesis; complex partnerships[J].Cell Mol Life Sci,2006,3:601-615.
  • 7Sandier A,Cray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355:2542-2550.
  • 8Herbst RS,Heymach JV,O'Reilly MS,et al.Vandetanib (ZD6474):an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis[J].Expert Opin Investig Drugs,2007,16:239-249.
  • 9Kaur B,Khwaja FW,Severson EA,et al.Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis[J].Neuro Oncol,2005,7:134-153.
  • 10Cherk MH,Foo SS,Poon AM,et al.Lack of correlation of hvpoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET[J].J Nucl Med,2006,47:1921-1926.
;
使用帮助 返回顶部